4//SEC Filing
Uihlein Richard E 4
Accession 0001133416-22-000043
CIK 0001133416other
Filed
Feb 7, 7:00 PM ET
Accepted
Feb 8, 9:25 AM ET
Size
8.1 KB
Accession
0001133416-22-000043
Insider Transaction Report
Form 4
Uihlein Richard E
Director10% Owner
Transactions
- Award
Stock Option (right to buy)
2022-01-24+40,000→ 40,000 totalExercise: $1.98Exp: 2032-01-24→ Common Stock (40,000 underlying) - Award
Common Stock
2022-01-24$1.98/sh+17,677$35,000→ 7,936,677 total
Holdings
- 27,710(indirect: By Foundation)
Common Stock
Footnotes (4)
- [F1]These restricted shares were issued pursuant to the Galectin Therapeutics Inc. 2019 Omnibus Equity Incentive Plan in lieu of a cash retainer and meeting fees of $35,000 for 2022. Restrictions on the shares lapse at a rate of 25% at the end of each calendar quarter in 2022.
- [F2]The reporting person is president and director of Ed Uihlein Family Foundation, a not-for-profit corporation. The reporting person has no pecuniary interest in the shares, however, he shares voting and dispositive power over the shares and, therefore, remains the beneficial owner of the shares solely for the purposes of Section 13(d) of the Securities Exchange Act of 1934.
- [F3]The options were issued pursuant to the Galectin Therapeutics Inc. 2019 Omnibus Equity Incentive Plan.
- [F4]The options vest 100% on December 31, 2022.
Documents
Issuer
GALECTIN THERAPEUTICS INC
CIK 0001133416
Entity typeother
Related Parties
1- filerCIK 0001694903
Filing Metadata
- Form type
- 4
- Filed
- Feb 7, 7:00 PM ET
- Accepted
- Feb 8, 9:25 AM ET
- Size
- 8.1 KB